48, p = 0.78) and C-reactive protein (r = 0.25, p = 0.88). A strong but not significant association is found between the overall quality of life assessed by the PedsQL 4.0 and visual function assessed by EYE-Q in the uveitis group (r = -0.64, p = 0.55). This study suggests that uveitis associated with JIA can present serious complications and could have a direct relationship with the activity of the JIA as well as with the quality of life of the patient.”
“Objectives: To determine if mixed connective tissue

learn more disease (MCTD) can be considered an independent clinical entity, to compare 3 different classification criteria for MCTD (Kasukawa, Alarcon-Segovia, and Sharp), and to define predictors (clinical features and autoantibodies) of potential evolution toward other connective tissue diseases (CTDs).\n\nMethods: One hundred sixty-one MCTD patients were evaluated retrospectively at the diagnosis and in 2008. They were classified, at the diagnosis, according to the 3 classification criteria of MCTD (Sharp, Alarcon-Segovia, and Kasukawa) and reclassified in 2008 according to their evolution. Statistical analyses were performed to find out predictors (clinical features and autoantibodies) of evolution into other CTDs.\n\nResults: After a mean of 7.9 years of disease, 57.9% of patients still satisfied MCTD classification

criteria of Kasukawa; 17.3% evolved into systemic sclerosis, 9.1% into systemic lupus erythematosus, 2.5% into rheumatoid arthritis, 11.5% ERK inhibitor clinical trial was reclassified as affected by undifferentiated connective tissue disease, and

1.7% as suffering from overlap syndrome. Kasukawa’s criteria were more sensitive (75%) in comparison to those of Alarcon-Segovia (73%) and Sharp (42%). The presence of anti-DNA antibodies (P = 0.012) was associated with evolution into systemic lupus erythematosus; hypomotility or dilation of esophagus (P < 0.001); and sclerodactyly (P = 0.034) with evolution into systemic sclerosis.\n\nConclusions: MCTD is a distinct clinical entity but mTOR inhibitor it is evident that a subgroup of patients may evolve into another CTD during disease progression. Initial clinical features and autoantibodies can be useful to predict disease evolution. (C) 2012 Elsevier Inc. All rights reserved. Semin Arthritis Rheum 41:589-598″
“From the aerial parts of Potentilla recta, ten compounds were isolated including a neolignan glycoside (1) and nine flavonoids (2-10). The structures of the isolates were elucidated by spectroscopic properties. The presence of a neolignan glycoside in the genus Potentilla is being reported for the first time by this work. Furthermore. compounds 9 and 10 are characterized for the first time from the genus Potentilla. The chemotaxonomic importance of these compounds was also summarized. (C) 2011 Elsevier Ltd. All rights reserved.